TMEM38B is a gene encoding TRIC-B (trimeric intracellular cation channel type B), a monovalent cation channel involved in intracellular calcium homeostasis. It works alongside TRIC-A to form heterotrimeric complexes that modulate calcium release from the endoplasmic reticulum (ER), critical for processes like muscle contraction, cell signaling, and apoptosis. TMEM38B mutations are linked to autosomal recessive osteogenesis imperfecta type XIV, a connective tissue disorder characterized by bone fragility and skeletal deformities. Antibodies targeting TMEM38B/TRIC-B are essential tools for studying its expression, localization, and functional roles in calcium signaling. They are widely used in Western blotting, immunofluorescence, and immunohistochemistry to investigate TRIC-B distribution in tissues such as bone, muscle, and kidneys. These antibodies also aid in exploring pathological mechanisms in disease models, including how TMEM38B loss affects ER calcium dynamics and collagen modification. Commercially available TMEM38B antibodies are typically raised against specific epitopes, often validated in knockout controls to ensure specificity. Research utilizing these antibodies has advanced understanding of TRIC-B's interplay with other calcium-regulating proteins (e.g., IP3 receptors, SERCA pumps) and its tissue-specific roles, particularly in bone formation and mineralization. Ongoing studies focus on its potential as a therapeutic target for calcium-related disorders.